Cover Image
市場調查報告書

皮膚肌炎:開發中產品分析

Dermatomyositis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 361637
出版日期 內容資訊 英文 105 Pages
訂單完成後即時交付
價格
Back to Top
皮膚肌炎:開發中產品分析 Dermatomyositis - Pipeline Review, H1 2017
出版日期: 2017年05月30日 內容資訊: 英文 105 Pages
簡介

皮膚肌炎是一種罕見的炎症性疾病,其特徵在於伴有肌肉無力的慢性肌肉發炎。皮肌炎的症狀包括獨特的皮疹,肌肉無力和發炎性肌病,或引起肌肉發炎。危險因素包括年齡和性別。治療可採用皮質類固醇。

本報告提供皮膚肌炎治療藥的開發情形相關調查,提供開發中產品概要,各臨床實驗階段的產品概要,主要企業及藥物簡介,開發中產品的最新趨勢,及最新消息/新聞稿等資訊。

簡介

  • 調查範圍

皮膚肌炎概要

治療藥的開發

  • 開發中產品的概要
  • 各企業的開發平台
  • 企業開發中的產品

皮膚肌炎:治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發皮膚肌炎治療藥的企業

  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Hope Pharmaceuticals Inc
  • Idera Pharmaceuticals Inc
  • KPI Therapeutics Inc
  • Marathon Pharmaceuticals LLC
  • MedImmune LLC
  • Neovacs SA
  • Novartis AG
  • Octapharma AG
  • Pfizer Inc

藥物簡介

皮膚肌炎:暫停中的計劃

皮膚肌炎:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9372IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dermatomyositis - Pipeline Review, H1 2017, provides an overview of the Dermatomyositis (Musculoskeletal Disorders) pipeline landscape.

Dermatomyositis is a rare inflammatory disease which is characterized by chronic muscle inflammation accompanied by muscle weakness. Symptoms of dermatomyositis include a distinctive skin rash, muscle weakness, and inflammatory myopathy, or inflamed muscles. Risk factors include age and gender. Treatment includes corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dermatomyositis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Dermatomyositis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dermatomyositis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dermatomyositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 3 and 2 respectively.

Dermatomyositis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dermatomyositis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Dermatomyositis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dermatomyositis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dermatomyositis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dermatomyositis (Musculoskeletal Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dermatomyositis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dermatomyositis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Dermatomyositis - Overview
    • Dermatomyositis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Dermatomyositis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Dermatomyositis - Companies Involved in Therapeutics Development
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • Hope Pharmaceuticals Inc
    • Idera Pharmaceuticals Inc
    • KPI Therapeutics Inc
    • Marathon Pharmaceuticals LLC
    • MedImmune LLC
    • Neovacs SA
    • Novartis AG
    • Octapharma AG
    • Pfizer Inc
  • Dermatomyositis - Drug Profiles
    • anabasum - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • baricitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dalazatide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMO-8400 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MEDI-7734 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MP-117 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • siponimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sodium thiosulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tocilizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tofacitinib citrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target IFN-Alpha for Metabolic Disorders, Immunology, Infectious Diseases and Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Dermatomyositis - Dormant Projects
  • Dermatomyositis - Product Development Milestones
    • Featured News & Press Releases
      • May 17, 2017: FDA Grants Octapharma USA Orphan Drug Designation for Octagam 10% for the Treatment of Dermatomyositis
      • May 11, 2017: Corbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Anabasum for the Treatment of Skin-Predominant Dermatomyositis
      • May 04, 2017: Neovacs to present clinical development update on IFNalpha Kinoid in dermatomyosis
      • Mar 09, 2017: Neovacs to present IFNalpha Kinoid technology and its clinical outlooks at upcoming Keystone Symposia Conference
      • Feb 09, 2017: Neovacs Issued New Broad Patent in China for IFNa Kinoid
      • Nov 29, 2016: Corbus Pharmaceuticals Commences One-Year Open-Label Extension to its Ongoing Phase 2 Study of Resunab (JBT-101) for Skin-Predominant Dermatomyositis
      • Sep 28, 2016: Corbus Announces Data on Effects of Resunab (JBT-101) in a Clinical Research Model of Resolution of Inflammation
      • Nov 09, 2015: Idera Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of IMO-8400 in Patients with Dermatomyositis
      • Oct 13, 2015: Corbus Pharmaceuticals to Present at the 14th Annual BIO Investor Forum
      • Aug 06, 2015: Corbus Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 13, 2015
      • Jul 13, 2015: Corbus Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Resunab for the Treatment of Dermatomyositis
      • Jun 16, 2015: Neovacs initiates clinical program in Dermatomyositis
      • Jun 16, 2015: Neovacs initiates clinical program in Dermatomyositis
      • Jun 05, 2015: Corbus Pharmaceuticals Expands Clinical Development of Resunab With a Phase 2 Trial for the Treatment of Rare Disease Dermatomyositis
      • May 13, 2015: Neovacs granted 1.8 million euros in research tax credit
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Dermatomyositis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Dermatomyositis - Pipeline by Eli Lilly and Company, H1 2017
  • Dermatomyositis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Dermatomyositis - Pipeline by Hope Pharmaceuticals Inc, H1 2017
  • Dermatomyositis - Pipeline by Idera Pharmaceuticals Inc, H1 2017
  • Dermatomyositis - Pipeline by KPI Therapeutics Inc, H1 2017
  • Dermatomyositis - Pipeline by Marathon Pharmaceuticals LLC, H1 2017
  • Dermatomyositis - Pipeline by MedImmune LLC, H1 2017
  • Dermatomyositis - Pipeline by Neovacs SA, H1 2017
  • Dermatomyositis - Pipeline by Novartis AG, H1 2017
  • Dermatomyositis - Pipeline by Octapharma AG, H1 2017
  • Dermatomyositis - Pipeline by Pfizer Inc, H1 2017
  • Dermatomyositis - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Dermatomyositis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top